Evaluation of the efficacy of topical ethyl vanillate in treatment of vitiligo
Not Applicable
Completed
- Conditions
- vitiligo.Vitiligo
- Registration Number
- IRCT201107317160N1
- Lead Sponsor
- Vice chancellor for research, Shiraz university of medical sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 25
Inclusion Criteria
Pateints with bilateral generalized depigmented lesions are selected among phototherapy patients. Pregnant women, children under 6 years of age, patients with past history of skin cancer, and patients taking immunosuppresive medications, are excluded from study.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Pigmentation of lesions. Timepoint: before intervention 1, 2, 3 months after intervention. Method of measurement: vitiligo area severity index scale.
- Secondary Outcome Measures
Name Time Method Erythema of lesion. Timepoint: at the end of months 1, 2, 3 after intervention. Method of measurement: taking photo.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms does ethyl vanillate utilize to enhance phototherapy in vitiligo treatment?
How does topical ethyl vanillate compare to standard-of-care treatments like corticosteroids for vitiligo?
Are there specific biomarkers that correlate with improved outcomes when using ethyl vanillate in vitiligo patients?
What are the potential adverse events associated with ethyl vanillate application in combination with phototherapy for vitiligo?
What related compounds or combination therapies are being explored alongside phototherapy for vitiligo treatment efficacy?